Locally Advanced and Recurrent Cervical Cancer: Current Landscape

Brian M. Slomovitz, MD, MS, FACOG

Professor, Florida International University Director, Gynecologic Oncology and Co-Chair, Cancer Research Committee Mount Sinai Medical Center Member, Board of Directors, GOG Foundation Uterine Cancer Lead, GOG Partners

Thursday, September 9, 2021



	No, nothing to disclose
X	Yes, please specify:


Company Name	Honoraria/ Expenses	Consulting/ Advisory Board	Funded Research	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	Other (please specify)
Merck		X						
GSK		X						
AstraZeneca		X						
Agenus		X						
GOG Foundation		X						
GNE/Roche		X						
Lill		X						
Akeso Biopharma		X						


Faculty Disclosure



Cervical Cancer is an International Health Concern


Cervical cancer incidence (527,624 cases)





Jung HS et al. J Clin Med. 2015. 4(5): 1126


Mortality: Incidence ratio: 50%








An Estimated 14,480 Cases of Invasive Cervical Cancer in the US in 2020²



1) SEER Stat Fact Sheets: Cervix Uteri Cancer. http://seer.cancer.gov/statfacts/html/cervix.html. 2) American Cancer Society. Cancer Facts & Figures 2021. Atlanta, GA: America

- Death rate in 2016 (2.2 per 100,000) was less than half that in 1975 (5.6 per 100,000)
- ✓ From 2007 to 2016, the death rate decreased by about 1% per year in women >50 years of age and older, but was stable in <50</p>






FIGO staging systems: differences between the 2009 and 2018 FIGO staging systems for cervical cancer

	FIGO 2009	FIGO 2018
1	Cervical carcinoma confined to the uterus (extension to the corpus should be disregarded)	Cervical carcinoma confined to the uterus (extension to the corpus should be disregarded)
IA (1	Invasive carcinoma diagnosed only by microscopy, with a maximum depth of invasion \leq 5.0 mm and largest extension \geq 7.0 mm	Invasive carcinoma diagnosed only by microscopy, with a maximum depth of invasion <5 mm
IA1	Measured stromal invasion with a depth of \leq 3.0 mm and a horizontal spread of \leq 7.0 mm	Measured stromal invasion with a depth of <3 mm
IA2	Measured stromal invasion >3.0 mm and <5.0 mm, with a horizontal spread of \leq 7.0 mm	Measured stromal invasion ≥3 mm, and <5 mm in depth
IB	Clinically visible lesion confined to the cervix or microscopic lesion greater than Stage IA	Invasive carcinoma with a maximum depth of invasion ≥5 mm (greater than Stage IA), lesion limited the cervix uteri
IB1	Clinically visible lesion ≤4.0 cm in greatest dimension	Invasive carcinoma \geq 5 mm depth of stromal invasion, and <2 cm in greatest dimension
IB2	Clinically visible lesion >4.0 cm in greatest dimension	Invasive carcinoma ≥2 cm and <4 cm in greatest dimension
IB3	N/A	Invasive carcinoma ≥4 cm in greatest dimension
П	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or lower third of the vagina	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or lower third of the vagina
IIA	Tumour without parametrial invasion	Tumour without parametrial invasion
IIA1	Clinically visible lesion ≤4.0 cm in greatest dimension	Invasive carcinoma <4 cm in greatest dimension
IIA2	Clinically visible lesion >4.0 cm in greatest dimension	Invasive carcinoma ≥4 cm in greatest dimension
IIB	Tumour with parametrial invasion	Tumour with parametrial invasion
III (1)	Tumour extending to the pelvic sidewall and / or involving the lower third of the vagina and / or causing hydronephrosis or non-functioning kidney	Tumour extending to the pelvic sidewall and / or involving the lower third of the vagina and / or causing hydronephrosis or non-functioning kidney and / or involves PLN and / or PALNs
IIIA	Tumour involving the lower third of the vagina but not extending to the pelvic wall	Tumour involving the lower third of the vagina but not extending to the pelvic wall
IIIB	Tumour extending to the pelvic wall and / or causing hydronephrosis or non-functioning kidney	Tumour extending to the pelvic wall and / or causing hydronephrosis or non-functioning kidney
IIIC1/2	N/A	Involvement of the PLN and / or PALNs, irrespective of tumour size and extent (with r and p notations*)
IVA	Spread to adjacent pelvic organs	Spread to adjacent pelvic organs
IVB	Spread to distant organs	Spread to distant organs

*Notations of r (imaging) and p (pathology) indicate the findings that are used to allocate the case to Stage IIIC. Pecorelli S. Int J Gynaecol Obstet 2009;105:103–104; Bhatla N, et al. Int J Gynaecol Obstet 2019;145:129–135.











Cervical cancer: summary of treatment



LEEP: Loop Electrosurgical Excision Procedure; PD-L1: Programmed Cell Death Ligand-1; MSIh: Microsatellite Instability High; dMMR: deficient Mismatch Repair 1. National Comprehensive Cancer Network. NCCN Cervical Cancer Guidelines version 1.2021. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed 10 June 2021; 2. National Cancer Institute. SEER Cancer Stat Facts: Cervical Cancer. https://seer.cancer.gov/statfacts/html/cervix.html. Accessed 10 June 2021




External Beam Radiation















X: 0.49 cm



















Treatment timing

- plus brachytherapy within 8 weeks¹
- Treatment extended beyond 8 weeks is associated with poorer outcomes¹ - It is possible that prolonging treatment beyond 8 weeks allows increased repopulation of cancer cells, resulting in reduced local control rates²



Treatment delay has been correlated with higher rates of pelvic failure, and current guidelines stipulate completion of EBRT




Effect of treatment time on pelvic control and survival³






- while minimizing adverse effects on normal tissue^{1,2}
- Imaging can improve the efficacy of brachytherapy³



A radioactive source is placed in or near the tumor, which allows for the tumor to receive a concentrated dose while relatively sparing the surrounding normal tissue¹

Brachytherapy


• Brachytherapy is the only method demonstrated to provide the high dose of radiation needed to control cervical cancer





Underutilization of Brachytherapy

- SEER data shows brachytherapy utilization decreased from 83% in 1988 to 58% in 2009 (p<0.001)¹
- survival (58.2% vs 46.2%, p<0.001)¹



1. Han K, et al. Int J Radiation Oncol Biol Phys 2013;87:111–119; 2. Mayadev J, et al. Gynecol Oncol 2018;150:73–78.

• Brachytherapy treatment was associated with higher 4-year cause-specific survival (64.3% vs 51.5%, p<0.001) and overall


- A study of patients with cervical cancer in California showed 45% brachytherapy utilization during the study period (2004–2014), with a subsequent decrease in survival outcomes (HR, 1.16; 95% CI, 1.01–1.34; p=0.0330) in patients who did not receive brachytherapy²
- There was also a disparity in patients treated with brachytherapy:²
 - Brachytherapy utilization was lower in patients aged >80 years and in patients at Stage IVA
 - Black patients and those in low socioeconomic situations had worse survival











1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 2.2020. https://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf. Accessed 19 September 2020.



Stage IB3, IIA2, IIB, III, IVA




OUTBACK: randomized Phase 3 trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared with chemoradiation alone

Study schema

Patients with cervical cancer suitable for chemoradiation with curative intent:

- FIGO 2008 Stage IB1+LN, IB2, II, IIIB, IVA
- ECOG 0–2
- Squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma
- No nodal disease above L3/4



Stratification factors:


- Pelvic or common iliac nodal involvement
- Requirement for extended-field radiotherapy
- FIGO 2008 stage: IB / IIA or IIB or IIIB / IVA
- Age <60 or \geq 60 years
- Hospital / site

Mileshkin LR, et al. Presented at ASCO Annual Meeting. 4–8 June 2021. LBA3.





OUTBACK: Key Efficacy Outcomes



Mileshkin LR, et al. Presented at ASCO Annual Meeting. 4-8 June 2021. LBA3.


Overall Survival					
		CRT	CRT +A	СТ	
	5yrOS	71%	72%		
	HR		= 0.8 Cl: 0.70-1. ²	17)	
12 24	4	36	48	60	
Time (month					
403 34		307	245	149	
417 34		306	244	164	

ACT did not significantly improve PFS or OS





OUTBACK: Patterns of Disease Recurrence



Sites of disease progression were **not significantly different** between the treatment arms and about **two-thirds of women** did not experience recurrence

Mileshkin LR, et al. Presented at ASCO Annual Meeting. 4–8 June 2021. LBA3.



OUTBACK: Sensitivity Analysis

Overall survival	Survival Rat CR CRT +AC		Hazard ratios from Cox regressions (95% CI)	m Interaction P P
Overall Survival				
Completed CRT	71% 749	6 +3.3 (-4 to 11) 0.37	0.81 (0.60-1.08)	0.15
				0.11
Did not complete CRT	73% 649	6 -9.2 (-24 to 5) 0.21	1.32 (0.77-2.25)	0.32
Progression-Free Survival Completed CRT	62% 669	<mark>∕₀ +4.8 (-3 to 12) 0.22</mark>	0.78 (0.60-1.00)	0.05
	000/ 540			0.12
Did not complete CRT	60% <mark>5</mark> 19	6 -8.6 (-23 to 6) 0.26	1.16 (0.75-1.80)	0.49

There was an absolute difference of 3% for OS, which was not greater than expected by chance alone

Mileshkin LR, et al. Presented at ASCO Annual Meeting. 4–8 June 2021. LBA3.




Lessons Learned from OUTBACK Trial

- 1. High drop out rate with switch maintenance strategy
- 2. With long post-progression survival, preferred endpoint is PFS
- 3. With almost 100% crossover, OS is not the preferred endpoint
- 4. Newer agents such as antiangiogenics and immunotherapy not studied



Advanced/Recurrent Cervical Cancer: A HIGH UNMET CLINICAL NEED!


Stage IVB Cervical Cancer



Winslow T. www.aacrfoundation.org/CancerTypes/Pages/PDQs/Cervical-Cancer-Treatment-PDQ.aspx. Accessed 15 January 2018.



A Phase III trial to assess the toxicity and efficacy of cisplatin doublet combinations in advanced and recurrent cervical cancer



• Monk BJ, et al. J Clin Oncol 2009; 27(28):4649-4655.

GOG-204: Study Design


Paclitaxel 135 mg/m2 over 24 hours and CDDP 50 mg/m² q3w, 6 cycles

Vinorelbine 30 mg/m2 IV bolus day1 and 8 and CDDP 50 mg/m² q3w, 6 cycles

Gemcitabine 1000mg/m² IV day 1 and 8 and CDDP 50 mg/m² IV day q3w, 6 cycles

Topotecan 0.75 mg/m² over 30 min days 1, 2, 3 CDDP 50 mg/m² IV day 1, q3w, 6

Quality of life was assessed for all regimens






- •Response rates for PC, VC, GC and TC were 29.1%, 25.9%, 22.3%, and 23.4%. Comparable toxicity except for leukopenia, neutropenia,
- infection and alopecia

• Monk BJ, et al. J Clin Oncol 2009; 27(28):4649-4655.

GOG-204: Results

Survival by Treatment Group





Stage IVB, persistent or recurrent cervical cancer; not amenable to curative surgery / radiotherapy

* Balancing factors:

- Tumors outside of the prior irradiation field
 - (yes or no)
- PS 0-1 or 2
- SCC or non-SCC
- Institution






Standard arm: TP Paclitaxel 135 mg/m² 24h d1 Cisplatin 50 mg/m² 2h d2

Experimental arm: TC Paclitaxel 175 mg/m² 3h d1 Carboplatin AUC 5 1h d1





Overall Survival



Kitagawa R, et al. J Clin Oncol. 2012;30(Suppl): Abstract 5006. J Clin Oncol. 2015 Jul 1;33(19):2129-35.



Events	Median(m)	68r	25 gr	3 g.g.
106	[16.1-22.9]	72.4%	38.8%	18.3%
98	[14725207.3]	67.6%	31.5%	21.3%

HR: 0.994 [90% CI: 0.789-1.253 (<1.29)] noninferiority one-sided $P = .032^{\#}$





R

A

Ν

D

0

Μ

Ζ

Ε

1:1:1:1



Carcinoma of the cervix

- Primary stage IVB
- Recurrent/persistent
- Measureable disease
- GOG PS 0-1
- No prior chemotherapy for recurrence (N = 452)

Stratification factors:


- Stage IVB vs recurrent/ persistent disease
- Performance status
- Prior cisplatin Rx as radiation-sensitizer






National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00803062. Accessed 15 January 2018.

GOG 240 Schema





GOG-0240: Final OS/PFS



• Tewari KS, et al. N. Engl J Med 2014;370:734-43.



Event, n (%)		Chemotherapy (n=219)	Chemotherapy + Bevacizumab (n=220)
GI events (grade ≥	:2) ^a	96 (44)	114 (52)
Fistula	GI	0	7 (3)
	GU	1 (<1)	6 (3)
	Total ^b	1 (<1)	13 (6)
Hypertension (grad	Hypertension (grade ≥2) ^c		54 (25)
Proteinuria (grade	≥3)	62 (28)	71 (32)
Neutropenia (grad	e ≥4)	57 (26)	78 (35)
Febrile neutropenia	a (grade ≥3)	12 (5)	12 (5)
Thromboembolism (grade ≥3)		3 (1)	18 (8)
CNS bleeding (grade ≥3)		0	0
GI bleeding (grade ≥3)		1 (<1)	4 (2)
GU bleeding (grad	e ≥3)	1 (<1)	6 (3)

 ^aExcluding fistulas. ^bFistulas were mainly managed supportively; one patient underwent colostomy, and another received nephrostomy tubes. ^cHypertension of grade 2 or higher was defined as recurrent or continuous hypertension for a period of more than 254 hours or a symptomatic increase in blood pressure by more than 20 mm Hg diastolic or to <150/100 mm HG if the blood pressure was previously normal. ^dBleeding was primarily managed with supportive therapy and transfusions of packed RBCs, most commonly in the outpatient setting.


- CNS, central nervous system; GI, gastrointestinal; GU, genitourinary; RBC, red blood cells.
- Tewari KS, et al. *N. Engl J Med* 2014;370:734-43.







Improving OS in Recurrent or Metastatic Cervical Cancer How do we move forward?



GOG 240 Cisplatin + Paclitaxel + Bevacizumab








Rationale for Immunotherapy

- •TCGA data
 - Amplifications in PD-L1/L2
 - Correlates with key immune cytolytic effectors
 - Can limit protective immunity
- Immunotherapy
 - PD-1/L1 inhibition
 - Promote T-cell activation against tumors
 - CTLA-4 inhibition
 - Enhances tumor-specific CD8+ T-cell responses


• TCGA, Nature 2017. Chen DS. Immunity 2013.



GOG FOUNDATION[®] 26



Mutational Burden Compared With Other Tumors



Alexandrov LB, et al. *Nature*. 2013;500(7463):415-421.



KEYNOTE 158: Study Design and Baseline Characteristics

Patients

Age ≥18 years

 Histologically or cytologically confirmed advanced cervical cancer

 Progression on/intolerance to ≥1 line of standard therapy

- ECOG PS 0 or 1
- Tumor sample for biomarker analysis

Endpoints

- Primary: ORR
- Secondary: DOR, PFS, OS

Median follow-up: 36.9 months Range: 34.3-41.0 months

Pembrolizum 200 mg Q3V

Baseline cl

Median age

ECOG PS 1

PD-L1+ tum

Number of p therapies

• ^aCPS ≥1

• Chung HC. Abstract 41. SGO Annual Meeting 2021.

nab W	Treat for 2 years ^a or until progression ^b intolerable toxicity, o study withdrawal			
haract	eristic, n (%)	N=98		
e (range)		46.0 (24-75)		
1		64 (65)		
nor ^a		82 (84)		
	1	44 (45)		
prior	2	31 (32)		
	3	13 (13)		
	≥4	8 (8)		
	1			




Outcome	Overall ^a N=98
ORR ^d , % (95% CI)	14.3 (8.0-22.8)
Best overall response, n (%)	
CR	5 (5.1)
PR	9 (9.2)
SD	16 (16.3)
PD	55 (56.1)
Non-evaluable ^e	4 (4.1)
No assessment ^f	9 (9.2)



- 65% of patients experienced any TRAE
- 12% had grade ≥3 TRAEs
- 4% had TRAEs leading to discontinuation
- ~25% of patients had any irAE; ~4% were grade ≥3, ~50% resolved
- 2% of patients discontinued pembrolizumab due to irAEs (hepatitis, n=2)
- alncludes 1 patient with unknown PD-L1 expression level. ^bCPS ≥1. ^cCPS <1. ^dAt the time of analysis, all responses were confirmed. ^eTarget lesions not captured on ≥1 post-baseline imaging assessment. Post-baseline tumor assessment not performed. gTRAEs leading to discontinuation included hepatitis (n=2), diarrhea (n=1), and stomatitis (n=1)
- Chung HC. Abstract 41. SGO Annual Meeting 2021.

KEYNOTE-158: Safety and Efficacy

Time to Response



Pembrolizumab received FDA approval for the treatment of PD-L1+ r/m cervical cancer; q6w dosing approved in April 2020





US FDA Accelerated Approval of Pembrolizumab (June 12, 2018)

<i>-{</i> ∦⊂ ∪.	U.S. Department of Health and Human Services								
FDA	DA U.S. FOOD & DRUG ADMINISTRATION								
=	Home	Food	Drugs	Medical Devices	Radiation-Emitting Products	Vac			
Druc	ls		-						

Home > Drugs > Drug Approvals and Databases > Approved Drugs

Approved Drugs	
Hematology/Oncology (Cancer) Approvals & Safety Notifications	i
Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)	
Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)	~

FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy

f Share | 🍠 Tweet in Linkedin

On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS \geq 1) as determined by an FDA-approved test.

Pembrolizumab was investigated in 98 patients with recurrent or metastatic cervical cancer enrolled in a single cohort of KEYNOTE 158 (NCT02628067), a multicenter, non-randomized, open-label, multi-cohort trial. Patients were treated with pembrolizumab intravenously at a dose of 200 mg every 3 weeks until unacceptable toxicity or documented disease progression. Among the 98 patients, approval was based on 77 (79%) patients who had tumors that expressed PD-L1 with a CPS ≥1 and who had received at least one line of chemotherapy for metastatic disease. PD-L1 status was determined using the PD-L1 IHC 22C3 pharmDx Kit.

U.S. FDA Press Release. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm. Accessed March 13, 2019.

	A to Z Index Follo	w FDA En Es	pañol	
	Search FDA			Q
ccines, Blood & Biologics	Animal & Veterinary	Cosmetics	Tobacco Products	



Companion Diagnostic PD-L1 IHC 22C3 CPS≥1




NCCN Guidelines: Systemic Therapy for Cervical Cancer

	Preferred regimens	Other recommended regimens	
Chemoradiation	Cisplatin, carboplatin if cisplatin intolerant	N/A	
First-line combinations	Cisplatin/paclitaxel/bevacizumab Carboplatin/paclitaxel/bevacizumab	Cisplatin/paclitaxel Carboplatin/paclitaxel Topotecan/paclitaxel ± bevacizumab Cisplatin/topotecan	
Possible first-line monotherapy	Cisplatin	Carboplatin or paclitaxel	
Second-line therapy	Pembrolizumab (for PD-L1+ or MSI-H/dMMR tumors)	Bevacizumab, albumin-bound paclitaxel, docetaxel, fluorouracil, gemcitabine, ifosfamide, irinotecan, mitomy pemetrexed, topotecan, vinorelbine Pembrolizumab for TMB-H tumors Larotrectinib or entrectinib for <i>NTRK</i> + gene fusion posit tumors	

• 1. NCCN. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 2.2020. https://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf. Accessed 19 September 2020.





ESMO VIRTUAL PLENARY





EMPOWER-CERVICAL 1/GOG-3016/ENGOT-CX9: RESULTS OF PHASE 3 TRIAL OF CEMIPLIMAB VS INVESTIGATOR'S CHOICE (IC) CHEMOTHERAPY (CHEMO) IN RECURRENT/METASTATIC (R/M) CERVICAL CARCINOMA

Krishnansu S Tewari,* Bradley J Monk,* Ignace Vergote, Austin Miller, Andreia Cristina de Melo, Hee Seung Kim, Yong Man Kim, Alla Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso, Fernanda Damian, Chih-Long Chang, Evgeniy A Gotovkin, Shunji Takahashi, Daniella Ramone, Joanna Pikiel, Beata Maćkowiak-Matejczyk, Eva Maria Guerra, Nicoletta Colombo, Yulia Makarova,

Jingjin Li, Shaheda Jamil, Vladimir Jankovic, Chieh-I Chen, Frank Seebach, David M Weinreich, George D Yancopoulos, Israel Lowy, Melissa Mathias, Matthew G Fury, and Ana Oaknin

12 May 2021



*Contributed equally to this presentation.






This study (NCT03257267) was sponsored by Regeneron Pharmaceuticals, Inc. and Sanofi.



EMPOWER: Interim Analysis of a Phase 3 trial of Cemiplimab versus Investigator's Choice Chemotherapy in R/M Cervical Carcinoma



*Performed according to ENGOT Model C.1+To account for differences in drug administration schedules, one cycle is defined as 6 weeks. AC, adenocarcinoma or adenosquamous carcinoma; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; IC, investigator's choice; IDMC, Independent Data Monitoring Committee; IV, intravenously; ORR, objective response rate; OS, overall survival; PD, pharmacodynamics; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; PK, pharmacokinetics; Q3W, every 3 weeks; QoL, quality of life; SCC, squamous cell carcinoma. 1. Vergote I et al. Int J Gynecol Cancer. 2019;0:1-4.

Cemiplimab 350 mg Q3W IV

IC chemotherapy

 Gemcitabine 1,000 mg/m² IV on Days 1 and 8 and every 21 days Topotecan 1 mg/m² daily IV for 5 days, every 21 days Irinotecan 100 mg/m² IV weekly x 4, followed by 10–14 days rest Vinorelbine 30 mg/m² IV on Days 1 and 8 and every 21 days

Treat up to 96 weeks with option for re-treatment

Tumour imaging conducted on Day 42 (± 7 days) of cycles[†] 1–4, 6, 8, 10, 12, 14, and 16

Primary endpoint: OS

Secondary endpoints: PFS, ORR, DOR, safety, QoL

Exploratory endpoints: PK, immunogenicity, biomarkers, PD

- Two interim analyses were prespecified per protocol
- At first interim analysis, IDMC recommended trial to continue
- At second interim analysis (85% of total OS events), IDMC recommended trial be stopped early for efficacy; presented here

- Opened: Sept 2017
- Closed: June 2020
- N = 590




• Sites = 105



33



SCC Population



Median duration of follow-up[‡]: 16.8 months (range: 6.0–38.2)

*Stratified by geographic region (North America vs Asia vs ROW) according to interactive web response system. [†]One-sided nominal *P* value, not adjusted for multiplicity. [‡]From randomisation to data cutoff date.

AC, adenocarcinoma or adenosquamous carcinoma; CI, confidence interval; HR, hazard ratio; mo, month; OS, overall survival; ROW, rest of world; SCC, squamous cell carcinoma.

Overall Survival

AC Population


Median duration of follow-up[‡]: 21.9 months (range: 6.9–36.6)





Overall Survival

• At second interim analysis (85% of total OS events), IDMC recommended trial be stopped early for efficacy



*Stratified by geographic region (North America vs Asia vs ROW) and Histology (SCC vs AC) according to interactive web response system. †From randomisation to data cutoff date. AC, adenocarcinoma or adenosquamous carcinoma; CI, confidence interval; HR, hazard ratio; IDMC, Independent Data Monitoring Committee; mo, month; ROW, rest of world; OS, overall survival.


Overall Population





Progression-free Survival

SCC Population



*Stratified by geographic region (North America vs Asia vs ROW) according to interactive web response system.

AC, adenocarcinoma or adenosquamous carcinoma; CI, confidence interval; HR, hazard ratio; mo, month; PFS, progression-free survival; ROW, rest of world; SCC, squamous cell carcinoma.

AC Population





Objective Response Rate

	Overall population		
By investigator assessment	Cemiplimab (n=304)	Chemotherapy (n=304)	
Response			
Objective response rate (ORR:CR+PR)	50 (16.4)	19 (6.3)	
95% CI for ORR ^a	(12.5, 21.1)	(3.8, 9.6)	
Best overall tumour response, n (%)			
Complete response (CR) ^b	10 (3.3)	3 (1.0)	
Partial response (PR) ^b	40 (13.2)	16 (5.3)	
Stable disease (SD) ^c	125 (41.1)	148 (48.7)	
Progressive disease (PD)	105 (34.5)	88 (28.9)	
Not evaluable (NE)	24 (7.9)	49 (16.1)	
Stratified CMH test one-sided <i>P</i> -value ^d	0.00004		
Odds ratio (95% CI) ^d	2.984 (1.707, 5.215)		
KM estimated median DOR, months (95% CI) ^e	16.4 (12.4, NE)	6.9 (5.1, 7.7)	
Median observed time to response, months (range)	2.7 (1.2–11.4)	1.6 (1.2–9.0)	

^aClopper-Person exact confidence interval (CI); ^bCR/PR must be confirmed by repeated assessments no less than 4 weeks apart; ^cSD criteria must be met at least once for a minimum duration of 4 weeks after first dose date; ^dOne-sided *P*-value and odds ratio using geographic region and histology stratified Cochran-Mantel-Haenszel (CMH) test. Due to the low response rate in the chemotherapy arm, the results from CMH test should be interpreted with caution; ^eBased on patients with confirmed CR or PR. AC, adenocarcinoma or adenosquamous carcinoma; DOR, duration of response; KM, Kaplan-Meier; SCC, squamous cell carcinoma.

ORR of SCC population

- ◆Cemiplimab: 17.6% (95% CI: 13.0– 23.0)
- Chemotherapy: 6.7% (95% CI: 3.9– 10.7)
- ORR of AC population
 - ♦Cemiplimab: 12.3% (95% CI: 5.5– 22.8)
 - Chemotherapy: 4.5% (95% CI: 0.9–) 12.7)










Mean Change From Baseline In GHS/Qol Scale

• MMRM Estimates



C, cycle; CI, confidence interval; D, day; GHS, Global Heath Status; IC, investigator's choice; LS, least squares; MMRM, mixed-model repeated measure; QoL, quality of life; SE, standard error.

Overall (SE)

Cemiplimab: 1.01 (1.54) Chemotherapy: -6.81 (2.12) Difference: 7.81, one-sided nominal *P*=0.00040

- Overall population: nominally significant difference in favour of cemiplimab over IC chemotherapy
- Patients receiving cemiplimab improved or maintained GHS/QoL from baseline
- Patients receiving chemotherapy generally showed deterioration in these scores







The Future is Bright

助

NAME AND ADD. NO. AND ADD IN

AND REAL PROPERTY.

A DELLA STRATE

of the Real Property and the Real Property lies and the Real Property in the Real Property lies ARE NOT THE REAL POLYNER, NAME AND ADDRESS OF THE POLYNER POLYNER, NAME AND States of the local division in the local di

...

